| abstract |
Provided herein is a pharmaceutical formulation comprising a modified IL-7 protein. More specifically, it comprises (a) a modified IL-7 fusion protein; (b) a base buffer at a concentration of 10 to 50 mM; (c) a sugar having a concentration of 2.5 to 5 w/v%; and (d) A surfactant having a concentration of 0.05 to 6 w/v%. The pharmaceutical formulation of the modified IL-7 fusion protein does not exhibit agglutination under stress conditions such as oxidation or agitation, but exhibits protective effects on the protein, and thus can be effectively used for treating patients. . |